Auriga raises its price target on Buy-rated JAZZ Pharmaceuticals JAZZ to $57 from $55 as the company posted another consensus-beating quarter.
Auriga says, "We remain impressed by Jazz's execution, as the company had another quarter of record revenue and EPS. The company also closed the Azur Pharma acquisition ahead of schedule, and we view 2012 guidance as being conservative. With its efficient tax structure and outstanding business execution, we think Jazz is well
positioned to grow via M&A, a strategy used successfully by Valeant Pharmaceuticals."
JAZZ closed at $50.55 a share on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in